59th ASH Annual Meeting & Exposition

Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Atlanta, GA, United States
Dec 09, 2017 - Dec 12, 2017
The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field as well as a global community of more than 25,000 hematology professionals from every subspecialty.
Visit the conference website for more details.

Oncology

Expert Opinion

featured

ASH 2017: Suggestions From Dr. Isabel Cunningham

Conference Coverage · December 06, 2017

ASH

News

ASH 2017: Venetoclax + Rituximab Proves Superior to Bendamustine + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

PracticeUpdate Editorial Team · December 14, 2017

ASH
ASH 2017: ADCT-402, A CD19-Directed mAB, Shows Encouraging Early Results in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

PracticeUpdate Editorial Team · December 14, 2017

ASH
featured

ASH 2017: bb2121 Anti-BCMA CAR T-Cell Therapy Leads to Durable Clinical Responses in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

PracticeUpdate Editorial Team · December 12, 2017

ASH
featured

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

HealthDay · December 12, 2017

ASH
ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

HealthDay · December 12, 2017

ASH
ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

HealthDay · December 12, 2017

ASH
ASH: New Approach to Gene Tx Restores Immune Cells in X-SCID

HealthDay · December 12, 2017

ASH
ASH 2017: Mutations in the SRP54 Gene Cause Severe Primary Neutropenia as Well as Shwachman-Diamond-Like Syndrome

PracticeUpdate Editorial Team · December 12, 2017

ASH
ASH 2017: The Investigational mAb Mogamulizumab Proves Superior to Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma

PracticeUpdate Editorial Team · December 12, 2017

ASH
ASH 2017: Consistently Strong Results Support the Addition of Daratumumab to Therapy for Transplant-Ineligible Newly Diagnosed Myeloma

PracticeUpdate Editorial Team · December 12, 2017

ASH

59th ASH Annual Meeting & Exposition

Expert Opinion

ASH 2017: Suggestions From Dr. Isabel Cunningham

News

ASH 2017: Venetoclax + Rituximab Proves Superior to Bendamustine + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

ASH 2017: ADCT-402, A CD19-Directed mAB, Shows Encouraging Early Results in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

ASH 2017: bb2121 Anti-BCMA CAR T-Cell Therapy Leads to Durable Clinical Responses in Heavily Pretreated Relapsed/Refractory Multiple Myeloma

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: New Approach to Gene Tx Restores Immune Cells in X-SCID

ASH 2017: Mutations in the SRP54 Gene Cause Severe Primary Neutropenia as Well as Shwachman-Diamond-Like Syndrome

ASH 2017: The Investigational mAb Mogamulizumab Proves Superior to Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma

ASH 2017: Consistently Strong Results Support the Addition of Daratumumab to Therapy for Transplant-Ineligible Newly Diagnosed Myeloma

No Content

Recently Updated